---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-053009"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:04.131855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome settles SUNOSI patent litigation; generic entry delayed to 2040

## Summary
- Alkem can sell generic SUNOSI on/after March 1, 2040 (no pediatric exclusivity) or September 1, 2040 (if granted), subject to FDA approval.
- Settlement resolves Alkem's ANDA patent litigation in District of New Jersey; similar litigation with another party remains pending.
- Agreement submitted to FTC and DOJ for review as required by law.
- No financial terms disclosed in the settlement.

## SEC filing metadata
- accession: 0001193125-26-053009
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526053009/0001193125-26-053009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526053009/axsm-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-053009
- JSON: https://secwatch.observer/filing/0001193125-26-053009.json
- Plain text: https://secwatch.observer/filing/0001193125-26-053009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.